Tangji Medical files for HKEX listing; core product is China's first endoscopic weight-loss device, with high-growth EBMT market

NewTimeSpace News: On 28 August 2026, Hangzhou Tangji Medical Technology Co., Ltd. filed a listing application with HKEX. Incorporated in 2016, the Company is a China-headquartered medical device company focused on providing innovative solutions for the treatment and comprehensive management of metabolic diseases. As of the last practicable date, it has one core product, the gastric bypass stent system (GBS), two other products and one digital health management platform that has obtained registration approval, together with 13 pipeline products.

The Company's core product GBS is a digestive endoscopic duodenal-jejunal bypass liner (DJBL) device for obesity, and the Company is expanding the approved indication of GBS to cover lower BMI (GBS-Low BMI). As the developer of China's first medical device approved for the endoscopic treatment of obesity, the Company has become a pioneer in advancing clinical applications in the metabolic disease field, offering treatment features distinct from pharmacotherapy and invasive bariatric surgery.

In terms of the market, according to Frost & Sullivan, China's obese patient population reached 233.7 million in 2025 (with obesity defined as BMI ≥ 28.0 kg/m² in China), expected to grow to 329.8 million by 2034; in 2025, the number of obese patients with MASH in China was 57.9 million, and the number of obese patients with type 2 diabetes reached 57.5 million. The global market for endoscopic bariatric and metabolic therapy (EBMT) devices is expected to grow from USD 148 million in 2025 to USD 1,248 million in 2030, representing a CAGR of 53.1%; in China, the EBMT device market is expected to grow from RMB 32 million in 2025 to RMB 1,352 million in 2030, representing a CAGR of 111.1%.

Led by a senior management team with extensive experience and insights in the medical device industry, the Company initiated the development of its core product GBS in 2017, and has successfully developed and commercialized one EBMT therapeutic device, with two complementary products facilitating device operation and one digital health management platform for comprehensive management having obtained registration approval; its pipeline covers indications including overweight, obesity, MASH with obesity and type 2 diabetes with obesity. The announcement cautioned that there is no guarantee that the Company will ultimately be able to successfully develop and market its core product or any pipeline product.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.